Predictive OncologyNASDAQ: POAI

Predictive Oncology Inc. (NASDAQ:POAI ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Glenn Garmont – Investor Relations Raymond Vennare – Chairman and Chief Executive Officer Josh Blacher – Chief Financial Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Second Quarter 2024 Earnings Conference Call.

PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of its common stock having a current exercise price of $14.00 originally issued in February 2021, June 2021 and May 2022, at a reduced exercise price of $1.32 per share. The issuance and/or resale of the shares of common stock issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form S-1 (File No. 333-267689), Form S-3 (File No. 254309) and Form S-3 (333-255582). The gross proceeds to Predictive Oncology from the exercise of the existing warrants are expected to be approximately $1.26 million, prior to deducting placement agent fees and transaction expenses payable by the Company.

Predictive Oncology's organ-specific in vitro models are designed to better mimic  the physiological environment of human tissue

Study successfully demonstrated Predictive's ability to build AI multi-omic machine learning models to predict survival outcomes among ovarian cancer patients better than clinical data alone Study successfully demonstrated Predictive's ability to build AI multi-omic machine learning models to predict survival outcomes among ovarian cancer patients better than clinical data alone

Predictive Oncology Inc. (NASDAQ:POAI ) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Glenn Garmont - IR Raymond Vennare - CEO and Chairman Josh Blacher - CFO Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q3 2023 Earnings Conference Call.

Predictive Oncology Inc. (NASDAQ:POAI) listed a number of recent milestones with the release of its third-quarter results, which also revealed a significant 22% reduction in its net loss. Chairman and CEO Raymond Vennare highlighted the delivery of successful results from its first campaign with Cancer Research Horizons, a subsidiary of the largest independent funder of cancer research in the world.

Predictive Oncology Inc announced that it has completed a multi-year study with UPMC Magee-Womens Hospital in Pittsburgh.  The science-driven company said the objective of the study was to evaluate the use of AI to build multi-omic machine learning (ML) models and test if these models can learn associations between the datasets and ovarian cancer patient short- and long-term survival.

Predictive Oncology, Inc. (NASDAQ:POAI ) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Glenn Garmont - Managing Director at LifeSci Partners Raymond Vennare - Chief Executive Officer and Chairman of the Board Bob Myers - Chief Financial Officer Pamela Bush - Chief Business Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Q2 2023 Earnings Conference Call.

Predictive Oncology reported its second-quarter financial results after the bell Thursday, including a significantly narrower loss than the same quarter of 2022.  The drug development company reported a loss of $0.98 per share, compared to $2.89 in the year-ago quarter.